Northland Capmk Forecasts Stronger Earnings for Brainsway

Key Points

• Northland Capmk has raised its FY2025 earnings per share estimate for Brainsway from $0.26 to $0.38, significantly above the current consensus of $0.08.
• Shares of Brainsway opened at $12.98, with a market cap of $245.32 million and a 52-week trading range between $7.06 and $13.65.
• Recent analyst upgrades include Northland Securities raising their price target to $19.00 and HC Wainwright increasing it to $17.00, both maintaining positive ratings on the stock.

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY - Free Report) - Research analysts at Northland Capmk boosted their FY2025 earnings per share estimates for shares of Brainsway in a report released on Wednesday, August 13th. Northland Capmk analyst C. Byrnes now expects that the company will earn $0.38 per share for the year, up from their previous forecast of $0.26. The consensus estimate for Brainsway's current full-year earnings is $0.08 per share. Northland Capmk also issued estimates for Brainsway's Q4 2025 earnings at $0.12 EPS.

A number of other analysts have also commented on the company. Northland Securities boosted their target price on Brainsway from $15.00 to $19.00 and gave the company an "outperform" rating in a research report on Thursday, August 14th. Wall Street Zen raised Brainsway from a "hold" rating to a "buy" rating in a research report on Sunday, August 17th. Finally, HC Wainwright raised their price target on shares of Brainsway from $16.00 to $17.00 and gave the company a "buy" rating in a research report on Thursday, August 14th. Two research analysts have rated the stock with a Buy rating, According to MarketBeat, Brainsway presently has an average rating of "Buy" and a consensus target price of $18.00.

Brainsway Trading Up 1.4%

Brainsway stock traded up $0.21 during midday trading on Monday, reaching $15.20. The stock had a trading volume of 72,373 shares, compared to its average volume of 67,490. Brainsway has a 12 month low of $7.06 and a 12 month high of $15.61. The company has a market capitalization of $287.28 million, a P/E ratio of 58.46 and a beta of 1.42. The company has a fifty day moving average price of $12.43 and a two-hundred day moving average price of $10.68.

Brainsway (NASDAQ:BWAY - Get Free Report) last issued its earnings results on Wednesday, August 13th. The company reported $0.10 EPS for the quarter, beating analysts' consensus estimates of $0.07 by $0.03. Brainsway had a return on equity of 8.97% and a net margin of 11.60%.The business had revenue of $12.63 million during the quarter, compared to analyst estimates of $12.34 million. Brainsway has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Brainsway

Several large investors have recently added to or reduced their stakes in the business. Two Sigma Investments LP lifted its position in Brainsway by 2.0% in the 4th quarter. Two Sigma Investments LP now owns 92,755 shares of the company's stock valued at $875,000 after acquiring an additional 1,786 shares in the last quarter. Cubist Systematic Strategies LLC grew its position in Brainsway by 14.6% in the 4th quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company's stock worth $181,000 after purchasing an additional 2,446 shares in the last quarter. Huntleigh Advisors Inc. grew its position in Brainsway by 5.7% in the 2nd quarter. Huntleigh Advisors Inc. now owns 77,416 shares of the company's stock worth $1,018,000 after purchasing an additional 4,143 shares in the last quarter. Lazard Asset Management LLC bought a new stake in Brainsway in the 4th quarter worth about $44,000. Finally, Raymond James Financial Inc. bought a new stake in Brainsway in the 2nd quarter worth about $85,000. Institutional investors own 30.11% of the company's stock.

Brainsway Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.